Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kojiro Tashiro

Showing results (41-50 of 96) with videos related to

Pageof 10
Sort By:
Anticancer Research|June 23, 2023
Effect of Adequate Local Radiation Dose on Oncological Outcomes in Localized Prostate Cancer Patients Treated With Low-dose-rate BrachytherapyYuki Enei, Fumihiko Urabe, Kenta Miki, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|August 31, 2023
Patients with PSA below 0.2 ng/mL at 8 years post high-dose-rate brachytherapy have an extremely low risk of subsequent recurrenceMinoru Nakazono, Fumihiko Urabe, Kosuke Iwatani, et al.
Anticancer Research|March 29, 2022
Low Body Weight as a Risk Factor for Apalutamide-related Cutaneous Adverse EventsMichie Katsuta, Takahiro Kimura, Kojiro Tashiro, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 12, 2024
Incidental Prostate Cancer in Radical Cystoprostatectomy Specimens is Associated with Worse Overall SurvivalTakahiro Kimura, Hajime Onuma, Shun Sato, et al.
The Prostate|October 17, 2024
Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone-sensitive prostate cancer: A multicenter studyTakafumi Yanagisawa, Wataru Fukuokaya, Shingo Hatakeyama, et al.
Anticancer Research|June 23, 2023
Treatment Results of High-dose-rate Brachytherapy and External Beam Radiation With Long-term Androgen Deprivation Therapy for Patients With Metastatic Prostate CancerHirotaka Suzuki, Fumihiko Urabe, Kosuke Iwatani, et al.
The Prostate|September 30, 2022
Long-term outcomes of radical prostatectomy versus low-dose-rate brachytherapy in patients with intermediate-risk prostate cancer: Propensity score matched comparisonFumihiko Urabe, Kenta Miki, Takahiro Kimura, et al.
International Journal of Clinical Oncology|May 25, 2023
The prognostic significance of the clinical T stage and Grade Group in patients with locally advanced prostate cancer treated via high-dose-rate brachytherapy and external beam radiationSoshi Kadena, Fumihiko Urabe, Kosuke Iwatani, et al.
Urologic Oncology|October 10, 2024
Clinical significance of PSA dynamics in castration-sensitive prostate cancer treated with ARSI doublet therapy: A multicenter studyFumihiko Urabe, Shingo Hatakeyama, Takafumi Yanagisawa, et al.
International Cancer Conference Journal|October 14, 2024
A case of pagetoid spread of urothelial carcinoma with notable reduction achieved through enfortumab vedotin, resulting in complete surgical resectionKenichi Tokuoka, Katsuki Muramoto, Keigo Sakanaka, et al.
Pageof 10

Showing results (41-50 of 96) with videos related to

Sort By:
Pageof 10
Anticancer Research|June 23, 2023
Effect of Adequate Local Radiation Dose on Oncological Outcomes in Localized Prostate Cancer Patients Treated With Low-dose-rate BrachytherapyYuki Enei, Fumihiko Urabe, Kenta Miki, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|August 31, 2023
Patients with PSA below 0.2 ng/mL at 8 years post high-dose-rate brachytherapy have an extremely low risk of subsequent recurrenceMinoru Nakazono, Fumihiko Urabe, Kosuke Iwatani, et al.
Anticancer Research|March 29, 2022
Low Body Weight as a Risk Factor for Apalutamide-related Cutaneous Adverse EventsMichie Katsuta, Takahiro Kimura, Kojiro Tashiro, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 12, 2024
Incidental Prostate Cancer in Radical Cystoprostatectomy Specimens is Associated with Worse Overall SurvivalTakahiro Kimura, Hajime Onuma, Shun Sato, et al.
The Prostate|October 17, 2024
Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone-sensitive prostate cancer: A multicenter studyTakafumi Yanagisawa, Wataru Fukuokaya, Shingo Hatakeyama, et al.
Anticancer Research|June 23, 2023
Treatment Results of High-dose-rate Brachytherapy and External Beam Radiation With Long-term Androgen Deprivation Therapy for Patients With Metastatic Prostate CancerHirotaka Suzuki, Fumihiko Urabe, Kosuke Iwatani, et al.
The Prostate|September 30, 2022
Long-term outcomes of radical prostatectomy versus low-dose-rate brachytherapy in patients with intermediate-risk prostate cancer: Propensity score matched comparisonFumihiko Urabe, Kenta Miki, Takahiro Kimura, et al.
International Journal of Clinical Oncology|May 25, 2023
The prognostic significance of the clinical T stage and Grade Group in patients with locally advanced prostate cancer treated via high-dose-rate brachytherapy and external beam radiationSoshi Kadena, Fumihiko Urabe, Kosuke Iwatani, et al.
Urologic Oncology|October 10, 2024
Clinical significance of PSA dynamics in castration-sensitive prostate cancer treated with ARSI doublet therapy: A multicenter studyFumihiko Urabe, Shingo Hatakeyama, Takafumi Yanagisawa, et al.
International Cancer Conference Journal|October 14, 2024
A case of pagetoid spread of urothelial carcinoma with notable reduction achieved through enfortumab vedotin, resulting in complete surgical resectionKenichi Tokuoka, Katsuki Muramoto, Keigo Sakanaka, et al.
Pageof 10